- HUTCHMED (China) Limited
- 20 August 2025 09:16:20
Source: Sharecast
The AIM-traded firm said the final patient was enrolled on 18 August.
It said the blinded, randomised study was evaluating the efficacy and safety of the two drugs in previously untreated patients with locally advanced or metastatic NSCLC with EGFR mutations and MET overexpression.
The study would compare the combination against Tagrisso alone, which is a current standard of care.
Hutchmed said the primary endpoint was progression-free survival, with other endpoints including overall survival, objective response rate and safety.
Topline results were expected in the second half of 2026, after which the company planned to submit data for presentation at a medical congress.
If successful, the results would support a supplementary new drug application filing with China’s National Medical Products Administration.
Hutchmed and AstraZeneca jointly developed Orpathys, a selective MET tyrosine kinase inhibitor, commercialised in China by AstraZeneca.
It was already approved in the country for NSCLC patients with MET exon 14 skipping alterations and, since June, for EGFR mutation-positive NSCLC with MET amplification after disease progression on EGFR TKI therapy in combination with Tagrisso.
Tagrisso, a third-generation EGFR inhibitor developed by AstraZeneca, had been used to treat over one million patients worldwide.
The company said the Sanovo study followed positive results from the ‘Sachi’ phase three trial in China and the ‘Savannah’ phase two study, which showed encouraging efficacy of the Orpathys-Tagrisso combination.
AstraZeneca and Hutchmed were also advancing the ‘Saffron’ phase three trial globally in the same patient group.
At 0812 BST, shares in Hutchmed China were flat at 241p.
Reporting by Josh White for Sharecast.com.